Cann is building a world-class business focused on breeding, cultivating and manufacturing medicinal cannabis for sale and use within Australia.
Recently the company was granted a licence to import and/or export cannabis genetics and medicinal cannabis products by the Australian Government Department of Health, through the Office of Drug Control (ODC).
As a holder of this licence, the Company can now apply for a permit to export raw cannabis material and cannabis oil for analytical testing.
To continue the next steps, Cann is heading to market with a capital raising in the form of a placement to institutional, sophisticated and other professional investors.
A share purchase plan will also be offered.
The halt will remain in place until the opening of trade on Monday 4th December 2017, or earlier if an announcement is made to the market.